TG THERAPEUTICS
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found o... n mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
TG THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
1993-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.tgtherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(212)554-4484
Email Addresses:
[email protected]
Total Funding:
205 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Apache
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - TG Therapeutics
Hercules Capital
Hercules Capital investment in Post-IPO Debt - TG Therapeutics
Official Site Inspections
http://www.tgtherapeutics.com Semrush global rank: 2.39 M Semrush visits lastest month: 7.67 K
- Host name: 172.67.73.137
- IP address: 172.67.73.137
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
